All In Biotech

Drug Trial Radar · NCT06046222

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of NS-229 in the Treatment of Eosinophilic Granulomatosis With Polyangiitis

Last checked: Nov 19, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Dec 20, 2023

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
NS Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Nippon Shinyaku Co., Ltd.
First posted
Sep 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.

Conditions

  • Eosinophilic Granulomatosis With Polyangiitis
  • Churg-Strauss Syndrome

Interventions

  • NS-229Drug

    Experimental

  • PlaceboDrug

    Placebo comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of subjects in remission [OGC 4.0]Time frame: From Baseline to week 28

Locations

34 sites in 8 countries. Site status is shown where the registry gives one.

  • National Jewish Health

    Denver, Colorado

  • Mayo Clinic

    Rochester, Minnesota

  • Cleveland Clinic

    Cleveland, Ohio

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University of Alberta

    Edmonton, Alberta, Canada

  • St Joseph's Healthcare Hamilton

    Hamilton, Ontario, Canada

  • University of Toronto

    Toronto, Ontario, Canada

  • CHU Nice

    Nice, France

  • Hopital Cochin

    Paris, France

  • Chu Rangueil

    Toulouse, France

  • Medius Kliniken gGmbh

    Kirchheim unter Teck, Studienzentrale, Germany

  • Istituto Auxologico Italiano IRCCS

    Milan, Italy

  • Fondazione Policlinico Universitario Campus Bio-Medico

    Roma, Italy

  • Azienda Provinciale per i Servizi Sanitari Provincia Autonoma Trento

    Trento, Italy

  • Azienda Ospedaliera Universitaria Integrata Verona

    Verona, Italy

  • Chiba University Hospital

    Chuo-ku, Chiba-shi, Chiba, Japan

  • Hospital of the University of Occupational and Environmental Health, Japan

    Kitakyushu, Fukuoka, Japan

  • Hokkaido University Hospital

    Sapporo, Hokkaido, Japan

  • NHO Sagamihara National Hospital

    Sagamihara, Kanagawa, Japan

  • National Hospital Organization Yokohama Medical Center

    Yokohama, Kanagawa, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, Japan

  • Osaka Habikino Medical Center

    Habikino, Osaka, Japan

  • Saitama Medical Center

    Kawagoe, Saitama, Japan

  • Juntendo University Hospital

    Bunkyo-ku, Tokyo, Japan

  • Kyorin University Hospital

    Mitaka, Tokyo, Japan

  • Toho University Omori Medical Center

    Ōta-ku, Tokyo, Japan

  • Complejo Hospitalario de Navarra

    Pamplona, Spain

  • Complejo Hospitalario Universitario de Santiago de Compostela

    Santiago de Compostela, A Coruna, Spain

  • Addenbrookes Hospital

    Cambridge, United Kingdom

  • Royal Berkshire NHS Foundation Trust

    Reading, United Kingdom

  • Queen Elizabeth Hospital Birmingham

    Edgbaston, Birmingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.